1 / 3

Braftovi shows a higher response rate in a triplet combination after adding Opdi

The Phase I/II study sponsored by BMS/Pfizer in collaboration with NCI evaluating the triplet combination of encorafenib cetuximab nivolumab in MSS mCRC patients who have received prior treatment with at least one, but not more than two systemic chemotherapy regimen for mCRC<br><br>For More Information- https://www.delveinsight.com/asco-conference/article/braftovi-microsatellite-stable-metastatic-colorectal-cancer?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

yashb
Download Presentation

Braftovi shows a higher response rate in a triplet combination after adding Opdi

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Braftovi shows a higher response rate in a triplet combination after adding Opdivo. Shifting focus towards microsatellite stable metastatic colorectal cancer (MSS CRC) patients ASCO 2022 Conference Braftovi in a triplet combination after adding Opdivo The Phase I/II study sponsored by BMS/Pfizer in collaboration with NCI evaluating the triplet combination of encorafenib + cetuximab + nivolumab in MSS mCRC patients who have received prior treatment with at least one, but not more than two systemic chemotherapy regimen for mCRC In September 2021, USFDA approved Braftovi (encorafenib) and Erbitux (cetuximab) combination to treat BRAF V600E mutated adult patients after prior therapy for mCRC based on the results from the BEACON Colorectal Cancer trial. The approval of the combination was not indicated in patients who were MSS, but the ongoing study is evaluating BRAF V600E who have MSS status.

  2. With a data cutoff of February 2022, all patients are enrolled: 26 evaluable for toxicity and 23 for the response. The median age was 60 years (range, 32-85), and 16 (62%) were female. Grade 3+ treatment-related adverse events (AE)occurred in 15% patients. The overall response rate was 50%, and the disease control rate was 96%. Median PFS is 7.4 months. For the 11 patients with responses, the median duration of response is 7.4 months. Median OS is 15.1 months. The median follow- up was 11.4 months; the median duration of response was 7.4 months. E-slices showed concordance between patients with radiographic responses and reduction in cell viability and between non-responders and increase in cell viability. KOL insights “Encorafenib, cetuximab, and nivolumab appear to be a safe and well-tolerated combination for microsatellite-stable BRAF-mutated metastatic colorectal cancer. The efficacy of this combination appears promising when considering the precedent of encorafenib and cetuximab alone from the previously reported BEACON study.”–Expert Opinion. Conclusion The triplet combination immunotherapy approach targets a subset of patients with Microsatellite-stable mCRC patients, for which immunotherapy alone has proven to be historically ineffective. Also, these patients often experienced rapid progression, and their disease has shown not to be responsive to standard chemotherapy as other mCRC patients do. Putting in to context, the findings from the Phase III BEACON trial, which led to the approval of encorafenib + cetuximab for previously treated BRAF V600E- mutated mCRC, the doublet combination was found to be effective only in 20% of patients with a median progression-free survival (mPFS) of 4 months and median overall survival (mOS) of 9.3 months. The results of the triplet combination are more significant if we compare it with the doublet combination. Additionally, another phase II (SWOG 2017) trial is underway to evaluate the encorafenib and cetuximab with or without nivolumab in the same patient segment. Latest Pharmaceuticals Market Research Reports 2022 by DelveInsight 1.Medical Marijuana Market 2.NPC Market

  3. 3.Tourette Syndrome Market 4.Oncolytic Virus Cancer Therapy Pipeline 5.Myeloproliferative Neoplasms Market 6.Shigellosis Market 7.CAR-T Pipeline 8.Urology Ultrasounds Devices Market 9.Myopia Treatment Devices Market 10.Alkaptonuria Market 11.Atopic Dermatitis AD Market 12.Axillary Hyperhidrosis Market 13.Fabry Disease Market 14.Rubella Market 15.Post-Transplant Lymphoproliferative Disorder Market 16.Coccidioidomycosis Market 17.Focal Segmental Glomerulosclerosis Market 18.Pigment Epithelial Detachment Market 19.Farber’s Disease Market 20.Advanced Liver Cancer Market 21.Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Market 22.Opioid-related Disorders Market 23.Myopia Progression Market Share 24.Chronic Venous Ulceration Market 25.Ptosis Market 26.Human Papillomavirus-positive Oropharyngeal Cancer Market 27.Trauma Fixation Devices Market 28.Eosinophilic Disorder Market 29.Epidemic Parotitis Market 30.Cystinuria Market 31.Familial Lipoprotein Lipase Deficiency Market

More Related